Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other financing activities (2023 - 2024)

Monte Rosa Therapeutics' Other financing activities history spans 2 years, with the latest figure at $229000.0 for Q4 2024.

  • For Q4 2024, Other financing activities fell 16.73% year-over-year to $229000.0; the TTM value through Dec 2024 reached $504000.0, changed N/A, while the annual FY2024 figure was $527000.0, 8.82% down from the prior year.
  • Other financing activities reached $229000.0 in Q4 2024 per GLUE's latest filing, down from $275000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $275000.0 in Q4 2023 to a low of $229000.0 in Q4 2024.